A private AI drug-discovery model raised a public proof question

Isomorphic Labs announced a proprietary artificial-intelligence model intended to improve how molecular interactions are predicted for drug discovery. The development extended the use of protein-structure systems into a less visible but consequential stage: choosing what to test before a possible medicine reaches the laboratory.

A better prediction can help researchers form hypotheses more efficiently, but it cannot turn a computed interaction into a treatment. Laboratory validation, toxicity work, manufacturing, and clinical studies remain separate tests that determine whether a candidate can help people.

The model was not publicly released, leaving outside scientists unable to test its claimed performance directly. The next proof is transparent evidence that candidates designed through the system survive independent laboratory and clinical evaluation.

Read the full story at Nature ↗